By Adriano Marchese
AnaptysBio shares plummeted in premarket trading Wednesday after the company said it will discontinue its dermatitis treatment after the drug failed to meet its targets in recent trials.
Shares fell over 39% to $14 ahead of the morning bell.
The clinical-stage biotechnology company said its investigational drug ANB032 didn't meet either primary or secondary endpoints in its 201-patient Arise-AD trial as a therapy for atopic dermatitis, often referred to as eczema.
Atopic dermatitis is a chronic disease that causes inflammation and irritation of the skin, often beginning at a young age.
"While ANB032 was safe and well tolerated, we're disappointed by these efficacy results in AD and will discontinue further investment in this asset," Chief Executive Daniel Faga said.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
December 11, 2024 09:36 ET (14:36 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。